Data / Drug companies / Dolgencorp, Inc. (dollar General & Rexall)
Dolgencorp, Inc. (dollar General & Rexall): 383 products in the FDA NDC directory, labeler code 55910
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Dolgencorp, Inc. (dollar General & Rexall) (labeler code 55910) lists 383 products in the FDA National Drug Code Directory, covering 146 finished drugs by generic name. By type: 383 over the counter drugs. Its main marketing category is over the counter monograph drugs. The newest product started marketing on July 13, 2026.
The request: Watch Dolgencorp, Inc. (dollar General & Rexall) (FDA labeler code 55910): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 55910
- Products in commercial distribution
- 383
- Packages
- 541
- Finished drugs by generic name
- 146
- Prescription products
- 0
- Over the counter products
- 383
- Flagged as original packager
- 359 of 359 products that carry the flag
- Started marketing in the last 12 months
- 8
- Products with a marketing end date set
- 24
- Earliest marketing start
- November 15, 1989
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 262 | 68.4% |
| Generic drugs (ANDA) | 108 | 28.2% |
| New drug applications (NDA) | 8 | 2.1% |
| Other unapproved drugs | 3 | 0.8% |
| Unapproved homeopathic products | 2 | 0.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 383 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 50 | 13.1% |
| Liquid | 39 | 10.2% |
| Tablet | 34 | 8.9% |
| Solution | 32 | 8.4% |
| Capsule, liquid filled | 31 | 8.1% |
| Tablet, chewable | 17 | 4.4% |
| Cream | 17 | 4.4% |
| Suspension | 14 | 3.7% |
| Spray | 12 | 3.1% |
| Ointment | 12 | 3.1% |
| Tablet, delayed release | 10 | 2.6% |
| Gel | 9 | 2.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Dg health ibuprofen | 55910-771 | Capsule, liquid filled | Generic drugs (ANDA) | July 13, 2026 |
| Dg health cough and chest congestion | 55910-774 | Solution | Over the counter monograph drugs | July 1, 2026 |
| Laxative | 55910-659 | Tablet | Over the counter monograph drugs | July 1, 2026 |
| Dg health day time intense flu | 55910-608 | Solution | Over the counter monograph drugs | July 1, 2026 |
| Dg health nicotine | 55910-669 | Lozenge | Generic drugs (ANDA) | June 26, 2026 |
| Aspirin | 55910-765 | Tablet | Over the counter monograph drugs | May 15, 2026 |
| Loperamide Hydrochloride | 55910-155 | Solution | Generic drugs (ANDA) | March 30, 2026 |
| DG Health Ibuprofen | 55910-650 | Capsule, liquid filled | Generic drugs (ANDA) | December 9, 2025 |
| Dollar General Menthol Pain Relief Gel Rollon | 55910-986 | Gel | Over the counter monograph drugs | October 1, 2025 |
| Dg health arthritis pain | 55910-926 | Gel | Generic drugs (ANDA) | July 30, 2025 |
| Laxative Gentle | 55910-723 | Tablet, delayed release | Over the counter monograph drugs | July 24, 2025 |
| Dg health cold flu relief | 55910-753 | Solution | Over the counter monograph drugs | June 30, 2025 |
| Dg health cold flu relief | 55910-142 | Solution | Over the counter monograph drugs | June 30, 2025 |
| Allergy Relief | 55910-450 | Tablet | Over the counter monograph drugs | June 24, 2025 |
| Nicotine Polacrilex | 55910-976 | Gum, chewing | Generic drugs (ANDA) | April 1, 2025 |
| DG health mucus er max | 55910-887 | Tablet, multilayer, extended release | Generic drugs (ANDA) | March 24, 2025 |
| DG HEALTH Liquid Antacid plus Anti Gas | 55910-670 | Suspension | Over the counter monograph drugs | March 17, 2025 |
| Allergy Relief | 55910-752 | Capsule, liquid filled | Over the counter monograph drugs | February 27, 2025 |
| DG Health Athletes Foot | 55910-118 | Cream | Over the counter monograph drugs | February 25, 2025 |
| DG HEALTH Ultra Strength | 55910-083 | Tablet, chewable | Over the counter monograph drugs | January 27, 2025 |
| DG HEALTH Regular Strength | 55910-049 | Tablet, chewable | Over the counter monograph drugs | January 27, 2025 |
| Cetirizine HCl | 55910-784 | Capsule | New drug applications (NDA) | November 25, 2024 |
| Mucus Relief DM Max | 55910-146 | Solution | Over the counter monograph drugs | October 7, 2024 |
| Dollar General Effervescent Pain Reliever | 55910-040 | Tablet, effervescent | Over the counter monograph drugs | August 1, 2024 |
| Sleep Aid | 55910-614 | Tablet, film coated | Over the counter monograph drugs | July 10, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.